Evidence map›Paper›PMID 24811250›Full record

ArticlePloS one2014

Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.

Hui Wang, Wei Sun, Wen-Zhong Zhang, Chun-Yan Ge, Jing-Tao Zhang, Zhong-Yan Liu, Yue-Zu Fan

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Hui WangDepartment of Surgery, Tongji Hospital, Tongji University School of Medicine, Tongji University, Shanghai, P.R. China.
Wei SunDepartment of Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Tongji University, Shanghai, P.R. China.
Wen-Zhong ZhangDepartment of Surgery, Shanghai Pudong New Area People's Hospital, Shanghai, P.R. China.
Chun-Yan GeDepartment of Oncology, Shanghai Yangpu Geriatric Hospital, Shanghai, P.R. China.
Jing-Tao ZhangDepartment of Surgery, Tongji Hospital, Tongji University School of Medicine, Tongji University, Shanghai, P.R. China.
Zhong-Yan LiuDepartment of Surgery, Tongji Hospital, Tongji University School of Medicine, Tongji University, Shanghai, P.R. China.
Yue-Zu FanDepartment of Surgery, Tongji Hospital, Tongji University School of Medicine, Tongji University, Shanghai, P.R. China.
Tongji Hospital · CNTongji University · CNPudong New Area People's Hospital · CNYangPu Geriatric Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vasculogenic mimicry (VM) is a newly-defined tumor microcirculation pattern in highly aggressive malignant tumors. We recently reported tumor growth and VM formation of gallbladder cancers through the contribution of the ephrin type a receptor 2 (EphA2)/focal adhesion kinase (FAK)/Paxillin signaling pathways. In this study, we further investigated the anti-VM activity of norcantharidin (NCTD) as a VM inhibitor for gallbladder cancers and the underlying mechanisms. In vivo and in vitro experiments to determine the effects of NCTD on tumor growth, host survival, VM formation of GBC-SD nude mouse xenografts, and vasculogenic-like networks, malignant phenotypes i.e., proliferation, apoptosis, invasion and migration of GBC-SD cells. Expression of VM signaling-related markers EphA2, FAK and Paxillin in vivo and in vitro were examined by immunofluorescence, western blotting and real-time polymerase chain reaction (RT-PCR), respectively. The results showed that after treatment with NCTD, GBC-SD cells were unable to form VM structures when injecting into nude mouse, growth of the xenograft was inhibited and these observations were confirmed by facts that VM formation by three-dimensional (3-D) matrix, proliferation, apoptosis, invasion, migration of GBC-SD cells were affected; and survival time of the xenograft mice was prolonged. Furthermore, expression of EphA2, FAK and Paxillin proteins/mRNAs of the xenografts was downregulated. Thus, we concluded that NCTD has potential anti-VM activity against human gallbladder cancers; one of the underlying mechanisms may be via blocking the EphA2/FAK/Paxillin signaling pathway.

Indexed as

AnimalsAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicCell Line, TumorCell ProliferationDown-RegulationEphrin-A2FemaleFocal Adhesion Protein-Tyrosine KinasesGallbladder NeoplasmsHumansMaleMiceMicrocirculationPaxillinSignal TransductionAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicEphrin-A2Focal Adhesion Protein-Tyrosine KinasesnorcantharidinPaxillin

Identifiers

PMID24811250
PMCPMC4014585
OpenAlexW2033418251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.